SCHEMBL67922

SCHEMBL67922

CC(C(=O)O)=P(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.42
CA4 P22748 1/20 0.42
CA5A P35218 1/20 0.42
USP2 O75604 1/20 0.40
AKR1C3 P42330 1/20 0.40
GAA P10253 1/20 0.40
ESR1 P03372 1/20 0.40
CES2 O00748 1/20 0.39
CES1 P23141 1/20 0.39
KMT2A Q03164 2/20 0.38
POLB P06746 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
CFTR P13569 1/20 0.38
NAPRT Q6XQN6 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MAPT P10636 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
TAAR1 Q96RJ0 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3995747 0.86 CES2 (0.44) CA2CA4CA5AUSP2ESR1
SCHEMBL4764636 0.82 MAPT (0.40) CA2CA4CA5AUSP2GAA
SCHEMBL28239030 0.80 CES2 (0.56) CES2CES1L3MBTL1NPSR1NAPRT
SCHEMBL24191888 0.79 CES2 (0.48) CA2CA4CA5AUSP2GAA
SCHEMBL1827594 0.79 POLB (0.46) CA2CA4CA5AGAAKMT2A
SCHEMBL4604853 0.76 CES2 (0.44) CA2CA4CA5AUSP2ESR1
SCHEMBL5190770 0.74 TSHR (0.41) CA2CA4CA5AGAAKMT2A
SCHEMBL52771 0.74 MEN1 (0.50) GAAKMT2APOLBNPSR1MAPT
SCHEMBL5568513 0.74 CA2 (0.43) CA2CA4CA5AUSP2GAA
SCHEMBL5179990 0.73 ALDH1A1 (0.59) GAAKMT2AL3MBTL1MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 789 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1347981-B1 CONDENSED PURINE DERIVATIVES AS A 1 ADENOSINE RECEPTOR ANTAGONISTS BIOGEN IDEC INC (US) 2008-05-07 EP claimed
EP-0918810-B1 LOW TEMPERATURE CURE CARBOXYL TERMINATED POLYESTERS RESOLUTION SPECIALTY MATERIALS (US) 2005-03-09 EP claimed
EP-0937038-B1 VITAMIN D ANALOGUES LEO PHARM PROD LTD (DK) 2002-04-17 EP claimed
JP-3109323-A None JP disclosed
JP-2193987-A None JP disclosed
US-12459922-B2 PARP7 inhibitors GILEAD SCIENCES, INC. (US) 2025-11-04 US disclosed
US-12441683-B2 7-methyl indole analogs and dosage forms containing the same Kuleon, LLC (US) 2025-10-14 US disclosed
US-20250282722-A1 7-METHYL INDOLE ANALOGS AND DOSAGE FORMS CONTAINING THE SAME KULEON LLC (US) 2025-09-11 US disclosed
EP-4469448-A1 PARP7 INHIBITORS GILEAD SCIENCES, INC. (US) 2024-12-04 EP disclosed
EP-4095133-B1 BENZIMIDAZOLONE-BASED CINNAMAMIDE DERIVATIVE AS TRPV1 ANTAGONIST AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF PAIN CONTAINING SAME AS ACTIVE INGREDIENT JMACKEM CO LTD (KR) 2024-07-24 EP disclosed
CN-117355521-A Heteroaryl inhibitors of plasma kallikrein 武田药品工业株式会社 2024-01-05 CN disclosed
EP-0290145-A1 Aliphatic carboxamides ZENECA INC. (US) 1988-11-09 EP disclosed
US-4729994-A Benzothiazepine vasodilators having aralkyl substitution MCNEILAB, INC. (US) 1988-03-08 US disclosed
EP-0091883-B1 PREEXTENSION CATALYSTS FOR EPOXY RESINS CIBA-GEIGY AG (CH) 1986-01-22 EP disclosed
US-4537964-A Method of preparing permissibly-substituted 1H(and 2H)pyrazolo[3,4-g]quinolines; pyrimido[4,5,g]quinolines; thiazolo[4,5,g]quinolines and intermediates therefore ELI LILLY AND COMPANY (US) 1985-08-27 US disclosed
US-4499299-A Pharmaceutically active phenylcarboxylic acid derivatives ICI AMERICAS INC. (US) 1985-02-12 US disclosed
US-4442099-A Leukotriene analogues RESEARCH CORPORATION (US) 1984-04-10 US disclosed
EP-0091883-A1 Preextension catalysts for epoxy resins CIBA-GEIGY AG (CH) 1983-10-19 EP disclosed
US-4125712-A PROSTAGLANDINS THE UPJOHN COMPANY (US) 1978-11-14 US disclosed
US-4125713-A PROSTAGLANDINS THE UPJOHN COMPANY (US) 1978-11-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250282722-A1 7-METHYL INDOLE ANALOGS AND DOSAGE FORMS CONTAINING THE SAME HTR7, HTR2C, HTR1A CA2 4598/4885CA4 4755/4885CA5A 4283/4885
US-12441683-B2 7-methyl indole analogs and dosage forms containing the same HTR7, HTR2C, HTR1A CA2 4598/4885CA4 4755/4885CA5A 4283/4885
US-12459922-B2 PARP7 inhibitors PARP1, PARP11, PARP2 CA2 3900/4885CA4 3542/4885CA5A 1408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.